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A B S T R A C T
Purpose: Evaluate the efficacy of carbamazepine in the treatment of idiopathic generalized epilepsy
(IGE).
Method: The response of five patients with IGE, who experienced primarily generalized tonic–clonic
seizures which were refractory to multiple antiepileptic drugs, is reported.
Results: Carbamazepine controlled multiple seizure types and did not induce or increase the frequency
of myoclonic or absence seizures in these patients. Many family members also responded favorably to
carbamazepine.
Conclusion: Carbamazepine can be used with caution as an alternative treatment option for refractory
IGE, especially in cases in which the main seizure type is generalized tonic–clonic.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Idiopathic generalized epilepsy generally responds well to
treatment with antiepileptic drugs (AEDs), with 80–90% achieving
seizure-freedom.1 Commonly used AEDs to successfully control
IGE include valproate (VPA), ethosuximide (ESX), lamotrigine
(LTG), and levetiracetam (LEV).1,2 Topiramate (TPM) and zonisa-
mide (ZNS) are also often considered ‘‘broad spectrum’’ AEDs, with
activity against primary generalized seizure types.2,3 The antiepi-
leptic drug carbamazepine (CBZ) has been reported to increase or
induce seizures in patients with IGE.1,4,5 CBZ has been shown to
exacerbate myoclonic and absence seizures and is therefore not
typically used in the treatment of IGE.6,7
Other than a case report suggesting that the addition of CBZ to
VPA in refractory juvenile myoclonic epilepsy (JME) treatment may
control tonic–clonic seizures only, we are not aware of any other
literature documenting successful treatment of IGE with CBZ.8
Additionally, we are not aware of any reported cases of IGE being
completely controlled with CBZ alone, or of CBZ controlling the
multiple seizure types that characterize IGE. Here we report five* Corresponding author at: Jefferson Comprehensive Epilepsy Center, Depart-
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tonic clonic seizures, whose seizures were controlled or dramati-
cally reduced in frequency due to treatment with CBZ.
2. Case histories
2.1. Patient 1
A 36-year-old woman had a 19-year history of JME character-
ized by generalized tonic–clonic seizures and myoclonus, but had
been seizure-free for 18 years on CBZ. Due to excessive daytime
sleepiness and a polysomnogram showing frequent persistent
generalized 4 Hz spike-wave activity, her CBZ had been discon-
tinued by in favor of VPA. She had recurrent generalized tonic–
clonic seizures, which were resistant to VPA (up to 1500 mg/day),
LEV (3000 mg/day), and TPM (100 mg/day). A brain MRI was
unavailable, but video-EEG monitoring verified both interictal
and ictal activity typical of JME, with 4 Hz spike-wave discharges
and non-localized generalized tonic–clonic seizures without
aura. Due to repeated seizures, CBZ was finally restarted, and she
has once again been seizure-free for five years on CBZ
monotherapy.
2.2. Patient 2
A 26-year-old woman presented with JME at age 13 years with
myoclonus, generalized tonic–clonic seizures, normal brain MRI,vier Ltd. All rights reserved.
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ized spike wave activity. She had been unable to tolerate multiple
AEDs, including phenytoin (PHT), TPM, LTG, and valproate due to
side effects or allergic reactions. Her seizures, occurring every 4–6
months, were refractory to several other AEDs, including ZNS
(300 mg daily), LEV (1250 mg), primidone (PRM) (500 mg), and
phenobarbital (PB) monotherapy (160 mg). CBZ was then added to
PB, and she became seizure-free. An attempt was made to wean
her PB, which resulted in recurrent myoclonic jerks with falls. She
has since been maintained on CBZ XR (1000 mg) and PB (90 mg)
and has remained seizure free for the past six years. She has three
family members with epilepsy, all of whom have been evaluated
at our epilepsy center. Her father, who has had myoclonus and
generalized tonic–clonic seizures since college and isolated bursts
of generalized spike-wave on EEG, has been seizure free since
2004 on a combination of PHT and PRM. Her sister and a paternal
cousin have also responded well to CBZ. Her sister is currently
seizure-free off AEDs, and her 56-year-old cousin has been
seizure-free on CBZ since adolescence. Both had normal routine
EEGs.
2.3. Patient 3
A 46-year-old man presented with a 26-year history of epilepsy.
An interictal EEG near the time of presentation demonstrated 4–
5 Hz generalized spike and wave and polyspike and wave activity.
He began having generalized tonic–clonic seizures at age 7, but
these were controlled on PHT until age 20 when status epilepticus
occurred following head trauma. After this, his seizures became
refractory to multiple AEDs, including PHT (400 mg), LEV
(2000 mg), VPA (3000 mg), LTG, ZNS (300 mg), and TPM
(800 mg). He was unable to tolerate clonazepam or gabapentin.
Several EEGs performed during this time period continued to
reveal generalized 4–5 Hz spike wave discharges, as well as
generalized tonic–clonic seizures beginning with generalized
polyspikes. Generalized tonic–clonic seizure frequency ranged
from several per week to one every 2–4 weeks, myoclonic seizure
frequency was less than one per month, and absence seizures
occurred occasionally (3 in one year). After CBZ XR (1200 mg) was
added to PHT (400 mg), his seizure frequency decreased to 2 GTC
seizures in 10 months, with occasional myoclonus, and no absence
seizures. The CBZ was subsequently replaced by oxcarbazepine
(1800 mg) in addition to PHT(300 mg) and has not had any seizures
for 1.5 years. He has two brothers with epilepsy (records
unavailable), one controlled on CBZ and LEV, and the other
controlled on PHT. His head CT was normal prior to head trauma.
Subsequently, he had additional head trauma with a subsequent
MRI brain showing only a subdural hematoma but no intrapar-
enchymal abnormalities.
2.4. Patient 4
A 51-year-old man with a history of generalized tonic–clonic
seizures beginning at age 14 years had experienced approximately
one generalized tonic–clonic seizure per year for many years while
treated with PHT. Due to gingival hyperplasia and continued
seizures, his PHT was tapered and replaced by LEV (1500 mg), but
his seizure frequency increased to once per month. Seizures
continued on ZNS (400 mg). EEG testing revealed 4-Hz generalized
spike wave discharges and a brain MRI was normal. He was thus
begun on VPA but continued experiencing frequent seizures with 3
seizures within one month, despite a therapeutic level (82 mg/L).
VPA was tapered, and CBZ XR (600 mg) was begun. He has been
seizure-free for 7 months. Of note, his sister, who is also treated at
our epilepsy center, has idiopathic generalized epilepsy and has
been seizure-free for two years on VPA.2.5. Patient 5
A 51-year-old woman with history of generalized tonic–clonic
seizures beginning in childhood and EEG with generalized 4 Hz
spike wave pattern had seizures refractory to TPM, LTG, VPA, LEV,
and ESX, with seizures occurring once every two to several months
on these medications. She was additionally unable to tolerate PHT
due to side effects. Her brain MRI showed nonspecific periven-
tricular white matter changes. She had been seizure-free on CBZ
monotherapy for 4.5 years, but this had been tapered (due to
alopecia) and replaced by oxcarbazepine (OXC). However, due to
continued seizures on oxcarbazepine (1050 mg), CBZ was restarted
and OXC tapered. She has been seizure-free for the past two years.
3. Discussion
Prior to treatment with CBZ, multiple AEDs had failed to provide
adequate seizure control for these patients. After starting CBZ,
these patients achieved full or significantly improved seizure
control. Rather than exacerbating or increasing absence and
myoclonic seizure frequency in these patients, a phenomenon
which has been documented as a potential consequence of CBZ use
in IGE treatment, CBZ also increased control of absence and
myoclonic seizures in one patient and of myoclonic seizures in two
patients. Notably, one patient also had improved seizure control on
OXC, a closely related compound. Additionally, two patients had
family members with epilepsy who achieved seizure control on
CBZ or PHT, which also affect the sodium channel and have been
reported to exacerbate seizures in IGE.5,6
As with all case histories, it is conceivable that the change in
seizure frequency in these patients was coincidental, rather than
being due to the introduction of CBZ, as spontaneous improve-
ments in epilepsy appear to be at least as common as medication
responses, at least in focal epilepsy.9 However, two patients
experienced recurrence of seizures upon CBZ withdrawal, regular
seizures on other drugs, and then regained long-term seizure-
freedom once ‘‘rechallenged’’ with CBZ, supporting that this was
indeed a drug-specific response.
These cases suggest that carbamazepine may offer an effective
treatment option for IGE that fails to respond adequately to AEDs
which are typically used as first-line treatment in this syndrome,
particularly when generalized tonic–clonic seizures are the
primary seizure type. However, it should be emphasized that
CBZ, particularly in monotherapy, should be used only with
caution, as it may also exacerbate seizures in some individuals
with IGE.
The response to atypical AEDs in family members with epilepsy
suggests that there may be a genetically predisposed response to
specific AEDs in some families. The existence of patients with IGE
that is specifically CBZ-responsive suggests that there is genetic
heterogeneity within the IGE syndromes, even those as well-
defined as JME. Further investigation is needed to determine why
some IGE cases respond well to CBZ, as well as whether a genetic
marker may be identified to indicate which patients may benefit
from treatment with CBZ.
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